Danny Hsu: Are Elastic Compression Stockings Ineffective in Preventing Post-Thrombotic Syndrome?
Danny Hsu, President of THANZ, shared on LinkedIn about a recent article by Jean-Philippe Galanaud et al, published in RPTH Journal:
”The Great Stocking Debate: It’s Not About ‘If,’ It’s About ‘How Much’
For years, the efficacy of Elastic Compression Stockings (ECS) in preventing Post-Thrombotic Syndrome (PTS) has been controversial.
Are they ineffective, or are they just sitting in the drawer?
This RPTH Journal publication sheds more light on the debate, courtesy of Dr Jean-Philippe Galanaud’s team.
A new prespecified analysis of the CELEST trial suggests that adherence is the independent predictor we’ve been looking for.
The Data: The ‘50%’ Threshold
This double-blind trial compared PTS rates at 2 years based on how often patients actually wore their stockings.
The results reveal a clear ‘tipping point’:
- < 50% Adherence: 38.4% PTS rate
- 50–79% Adherence: 24.5% PTS rate
- ≥ 80% Adherence: 27.5% PTS rate
Clinical Pearl: The “All or Nothing” Myth
Perfection isn’t required. Wearing ECS ≥50% of the time significantly decreased the risk of PTS (aOR=0.51).
Who Benefits the Most?
The study identified a specific phenotype where adherence yields the highest return.
Non-obese patients with extensive DVT (≥4 venous segments) saw a massive benefit:
- Adherent (≥50%): 29.8% developed PTS
- Non-Adherent: 54.3% developed PTS
Risk Factors for PTS Identified:
- Obesity (aOR=4.73)
- Extensive DVT (≥4 segments aOR=15.59)
- Patient height
The Verdict:
Adherence matters, but we can be realistic with our patients.
Aiming for at least 50% wear time makes a clinically significant difference, particularly for our high-risk patients with extensive proximal DVT.
Does this data change how you counsel patients on compression adherence?”
Title: Impact of Adherence on Elastic Compression Stockings Efficacy to Prevent Post-Thrombotic Syndrome: a Prespecified Analysis of the CELEST Study
Authors: Jean-Philippe Galanaud, Céline Genty-Vermorel, Béatrice Terriat, Audrey Stansal, Damien Lanéelle, Claire Grange, Myriam Martin, Francis Couturaud, Patrick Mismetti, Alexa Comte, Claire Eychenne, François Verrière, Jean-Luc Bosson, CELEST investigators
Read the Full Article on RPTH Journal

Stay updated on all scientific advances with Hemostasis Today.
-
Feb 18, 2026, 16:47Sophia Delicou: Importance of Assessing Hemoglobin Functional Capacity Rather Than Total Levels
-
Feb 18, 2026, 16:32Cheng-Hock Toh: 5 Steps to Transform Transfusion Practice
-
Feb 18, 2026, 16:26Tareq Abadl: CMV and Transfusion – Leukoreduction vs CMV-Seronegative
-
Feb 18, 2026, 16:24Soroush Sohrabi: The Hidden Biology of Sclerotherapy and Mechanisms Beyond Endothelial Injury
-
Feb 18, 2026, 16:23Hamad Abbasi: Why are Coronary Stents so Expensive?
-
Feb 18, 2026, 16:08Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
-
Feb 18, 2026, 16:05Shiny K. Kajal: Routine vs Massive Transfusion Protocol
-
Feb 18, 2026, 16:03Maria Farid: Successful Consultative Hematology and Transfusion Medicine Workshop at PKLI
-
Feb 18, 2026, 15:59Ella Lawson: Could Erythritol Harm the Brain’s Blood Vessels?